PP’s product for dry AMD is a zinc supplement, not a drug.
I would not necessarily assume it is going to be OTC - in fact the company talks of 'prescribers'. I have not assessed how realistic that is - but it is not completely unheard of (e.g. lithium is in some multivitamins and yet is also prescribed).
Dry AMD is definitely a huge opportunity. Lucentis *could* have been a $2B drug...rumor at AAO was that DNA may actually be looking to DIVEST because of Avastin problem (probably untrue).
Only 2 real contenders for dry in the clinic today (Othera and Sirion - both private), but as in wet, there will likely be a mad rush to 'repurpose' drugs once one of these shows Ph2 efficacy.
Market Data 
Markets 
AI
